top of page
  • LinkedIn
  • Facebook
  • Twitter

24 items found for ""

  • Vivacelle Bio and University of Missouri-Kansas City School of Medicine Announce Groundbreaking Results from Phase 2a Clinical Trial of VBI-S for Refractory Hypotension in Severe Septic Shock Patients

    https://www.prnewswire.com/news-releases/vivacelle-bio-and-university-of-missouri-kansas-city-school-of-medicine-announce-groundbreaking-results-from-phase-2a-clinical-trial-of-vbi-s-for-refractory-hypotension-in-severe-septic-shock-patients-302074945.html KANSAS CITY, Mo., Feb. 29, 2024 /PRNewswire/ -- Today, researchers at Vivacelle Bio, Inc., a pioneering biotechnology company revealed the compelling outcomes of their phase 2a clinical trial of the investigational cardiovascular support fluid, VBI-S, in patients with severe septic shock. This landmark study now published in the Lancet's eClinicalMedicine , showcases the potential of VBI-S in transforming the treatment landscape for refractory hypotension in these critically ill patients. Unlike previous septic shock trials, this study, conducted in collaboration with the University of Missouri- Kansas City School of Medicine, there were no restrictions on the severity or duration of the illness or the cardiorespiratory stability of the enrolled patients. Some patients were unstable when given VBI-S. Yet the primary endpoint was achieved in each case. Twenty patients with high doses of vasopressors, multiple organ system failure, and a severely dysregulated response to infection were enrolled in the study. Patients, after failing standard fluids, received intravenous VBI-S, a revolutionary composition of phospholipid nanoparticles that reversibly absorb nitric oxide. The results were astonishing, with VBI-S proving 100% effective in elevating mean blood pressure by 10 mmHg or more. Within just 48 hours of the infusion, there were statistically significant improvements across multiple parameters, including oxygenation, renal function, inflammation, lactic acid levels, prothrombin time, and international normalized ratio. Furthermore, the sequential organ failure assessment (SOFA) score, a key indicator of illness severity, showed a notable decrease, signifying improved patient conditions. Remarkably, no serious adverse events were attributed to VBI-S. Sepsis, affecting 49 million people worldwide and claiming eleven million lives annually, poses a significant global health challenge. In the United States alone, 357,000 people succumb to sepsis each year. The efficacy and safety demonstrated by VBI-S in reversing hypotension, inflammation, and organ failure in septic shock patients suggest a potential paradigm shift in treating sepsis with its associated high mortality and morbidity. Dr. Cuthbert Simpkins, MD, the Sosland Missouri Endowed Chair in Trauma Services at the University of Missouri Kansas City School of Medicine and Chief Innovation Officer of Vivacelle Bio, Inc. stated, "This study was initially intended as a pilot to determine the variability of VBI-S effects. We did not expect the convincing results that we obtained. These results fuel our optimism that at last we may have an effective and safe intervention for these very sick patients." Harven DeShield, J.D., Ph. D., CEO of Vivacelle Bio, added, "Ultimately, the availability, affordability, and accessibility of VBI-S would represent a paradigm shift, substantially transforming how septic shock is treated both in the US and globally upon FDA's clearance of VBI-S to be marketed to the public." In a statement, Rod Cotton, 2Flo Ventures Advisory Board Member said, "The publication of  these clinical trial results in such a highly regarded peer reviewed journal is evidence of the importance of Vivacelle Bio's technology. This article is the introduction of a new concept of medical intervention that will revolutionize the treatment of sepsis and a broad-spectrum of medical conditions bringing hope to patients and their families." 2Flo Ventures is a startup studio and venture capital firm, and investor in Vivacelle Bio. This groundbreaking research opens new possibilities for the treatment of septic shock, offering hope and potential survival for millions of patients worldwide. The implications of VBI-S in reshaping the landscape of septic shock treatment are promising, marking a significant step forward in the fight against this life-threatening condition. This work was supported by the Naval Medical Research Command (NMRC) - Naval Advanced Medical Development (NAMD) Program under MTEC award 20-02-NavyMultiTopic-002. About MTEC The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. For more information about MTEC, visit mtec-sc.org. About 2Flo Ventures 2Flo Ventures is a startup studio and venture capital firm dedicated to accelerating equitable innovation in healthcare. They invest in diverse healthcare entrepreneurs and companies built to close gaps in health outcomes for underserved communities. About Vivacelle BioVivacelle Bio (www.vivacellebio.com) is a life sciences company that utilizes patented phospholipid nanoparticle technology to design products that increase the survivability of critically-ill patients. In addition to VBI-S and VBI-1, Vivacelle Bio has a pipeline of products at various stages of development applicable to a range of health areas including reperfusion injury, organ preservation and transplantation, multiple organ dysfunction syndrome and hyperprocalcitonemia.  Vivacelle Bio has raised approximately $10.9M in seed and Series A1-A3 funding, including from the US Department of Defense, the US National Institutes of Health, and 2Flo Ventures. Forward looking statements This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (I) change without notice, (ii) factors beyond the Company's control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. SOURCE Vivacelle Bio

  • Vivacelle Bio Integrates Sub-Saharan Africa Strategy into Series B Financing Round

    https://www.prnewswire.com/news-releases/vivacelle-bio-integrates-sub-saharan-africa-strategy-into-series-b-financing-round-302067989.html

  • Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats

    Feds hope to cut sepsis deaths by hitching Medicare payments to treatment stats. https://www.fiercehealthcare.com/providers/feds-hope-cut-sepsis-deaths-hitching-medicare-payments-treatment-stats The rule emphasizes the following measures: Quick Blood Tests: Hospitals must perform blood tests promptly to identify markers indicating sepsis.Timely Antibiotics: Antibiotics must be administered within three hours of identifying a possible sepsis case.Other Measures: The Severe Sepsis/Septic Shock Early Management Bundle also includes additional tests and intravenous fluids to maintain safe blood pressure levels.

  • Vivacelle Bio’s VBI-S Phase IIa Clinical Trial Meets Primary and Secondary Endpoints for Treating Hypovolemia in Septic Shock Patients

    KANSAS CITY, Mo., Feb. 10, 2023 /PRNewswire/ -- Vivacelle Bio, Inc., a privately held life science company focused on the development of treatments for hypovolemia in shock including septic shock and hemorrhagic shock, announced the successful completion of its Phase IIa clinical trial of VBI-S in septic shock patients with severe hypovolemia. Severe septic shock patients experience a drastic drop in blood pressure that is associated with multiple organ failure causing patient death. While conventional fluids are effective for treating absolute hypovolemia, they are ineffective for treating relative hypovolemia, which is caused by excessive production of nitric oxide (NO) in septic shock. VBI-S, which is administered intravenously, reversibly absorbs NO, reducing the bioavailability of NO. This first of its kind approach reduces the bioavailability of NO without interfering with its production or essential cellular interactions. In the VBI-S Phase IIa trial, reversal of relative hypovolemia led to an increase in blood pressure and improvement of organ function. All 20 patients enrolled in the trial met the primary endpoint of elevating mean arterial blood pressure by at least 10 mmHg within an average of 1.5 hours. The secondary endpoint which was to reduce the dose of vasopressors was also met. Significant improvements in tissue perfusion, inflammation, kidney and lung function were also observed within 48 hours, with no drug-related adverse effects reported. The mortality rate of patients with septic shock is approximately forty percent (40%) with 270,000 deaths per year in the United States and eleven (11) million deaths per year worldwide. Reversal of the drop in blood pressure and improvement of organ function by targeting relative hypovolemia with VBI-S infusion in septic shock patients could be significantly important for improving the chance of survival of these patients. Cuthbert Simpkins MD, the Sosland Missouri Endowed Chair in Trauma Services at the UMKC School of Medicine in Kansas City and the Chief Innovation Officer of Vivacelle Bio, Inc. stated, "We could not have imagined a better outcome for our clinical trial. We believe VBI-S is what physicians have been seeking for decades. We are very excited to have created a novel treatment for hypovolemia due to septic shock much different from the multiple treatment approaches for this life-threatening disease that do not work." Harven DeShield JD, Ph.D., the CEO of Vivacelle Bio, Inc. commented, "contingent upon Food and Drug Administration (FDA) clearance, VBI-S represents a paradigm shift in the treatment of hypovolemia due to septic shock because it is very likely to markedly reduce the probability of a patient being placed on Extracorporeal Membrane Oxygenation (ECMO) after the failure of fluid therapy and vasopressors and potentially improve survival of patients." The clinical trial is funded by the Naval Medical Research Center (NMRC) – Naval Advanced Medical Development (NAMD) program via the Medical Technology Enterprise Consortium (MTEC). About MTEC The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. For more information about MTEC, visit mtec-sc.org. For more information on VBI-S or Vivacelle Bio, Inc., please contact Harven DeShield, J.D., Ph.D., CEO, at 716-830-8932 or via email, harven@vivacellebio.com. Forward looking statements This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this press release about future events are subject to (I) change without notice, (ii) factors beyond the Company's control and (iii) the financial capabilities of the Company. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results, performance or achievements to be materially different from the expected results, performance or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. Contacts Harven DeShield, J.D., Ph.D., CEO716-830-8932harven@vivacellebio.com.

  • Septic Shock Market is Expected to Expand at a Healthy Growth Rate by (2022-2032), States DelveInsight | Key Companies – Adrenomed AG, Vivacelle Bio, Inotrem

    By GetNews Published September 19, 2022 DelveInsight’s “Septic Shock Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Septic Shock, historical and forecasted epidemiology as well as the Septic Shock market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Septic Shock market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Septic Shock pipeline products will significantly revolutionize the Septic Shock market dynamics. Septic Shock Overview According to the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis3), septic shock is defined by persisting hypotension that requires vasopressors to maintain amean arterial pressure of 65 mm Hg or higher and a serum lactate level greater than 2 mm ol/L(18 mg/dL) despite adequate volume resuscitation. The symptoms of septic shock include hypotension, confusion or disorientation, diarrhea, nausea and vomiting, cold, clammy, and pale skin. Some of the key facts of the Septic Shock Market Report: The Septic Shock market size is anticipated to grow with a significant CAGR during the study period (2019-2032) Sepsis-2 septic shock accounted for three-quarters of the severe sepsis population, and the extrapolated population incidence increased from 69–79 per 100,000 person-years Key Septic Shock Companies: Adrenomed AG, Vivacelle Bio, Inotrem, and others Key Septic Shock Therapies: Adrecizumab, VBI-S, Nangibotide, and others The Septic shock epidemiology based on gender analyzed that the percentage of females who stayed in ICU due to septic shock was 36.7% Get a Free sample for the Septic Shock Market Report Key benefits of the Septic Shock Market report: Septic Shock market report covers a descriptive overview and comprehensive insight of the Septic Shock Epidemiology and Septic Shock market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.) The Septic Shock market report provides insights on the current and emerging therapies. Septic Shock market report provides a global historical and forecasted market covering drug outreach in 7MM. The Septic Shock market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Septic Shock market. Discover more about therapies set to grab major Septic Shock market share @ Septic Shock market forecast Septic Shock Epidemiology Segmentation: The Septic Shock market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Septic Shock Prevalent Cases of Septic Shock by severity Gender-specific Prevalence of Septic Shock Diagnosed Cases of Episodic and Chronic Septic Shock Septic Shock Market The dynamics of the Septic Shock market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Adrecizumab, VBI-S, Nangibotide, and others during the forecasted period 2019-2032. Download the report to understand which factors are driving Septic Shock epidemiology trends @ Septic Shock Epidemiological Insights Septic Shock Therapies and Key Companies Adrecizumab: Adrenomed AG VBI-S: Vivacelle Bio Nangibotide: Inotrem Scope of the Septic Shock Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Septic Shock Companies: Adrenomed AG, Vivacelle Bio, Inotrem, and others Key Septic Shock Therapies: Adrecizumab, VBI-S, Nangibotide, and others Septic Shock Therapeutic Assessment: Septic Shock current marketed and Septic Shock emerging therapies Septic Shock Market Dynamics:  Septic Shock market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL’s views, Analyst’s views, Septic Shock  Market Access and Reimbursement Table of Contents 1. Septic Shock Market Report Introduction 2. Executive Summary for Septic Shock 3. SWOT analysis of Septic Shock 4. Septic Shock Patient Share (%) Overview at a Glance 5. Septic Shock Market Overview at a Glance 6. Septic Shock Disease Background and Overview 7. Septic Shock Epidemiology and Patient Population 8. Country-Specific Patient Population of Septic Shock 9. Septic Shock Current Treatment and Medical Practices 10. Septic Shock Unmet Needs 11. Septic Shock Emerging Therapies 12. Septic Shock Market Outlook 13. Country-Wise Septic Shock Market Analysis (2019–2032) 14. Septic Shock Market Access and Reimbursement of Therapies 15. Septic Shock Market drivers 16. Septic Shock Market barriers 17.  Septic Shock Appendix 18. Septic Shock Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight To know more about Septic Shock treatment, visit @ Septic Shock Medications Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/

  • Sepsis And Septic Shock Treatment Market Hitting New Highs By 2028 | VBI-S: Vivacelle Bio, Nangibotide (LR12): Inotrem, Allocetra: Enlivex Therapeutics

    Published May 9, 2022 New Jersey, United States-Sepsis and Shock Treatment Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028 The report on the worldwide sepsis and shock treatment market concentrates on the past as well as flow development patterns and chances to acquire important experiences of these pointers for the market during the figure time frame from 2021 to 2028. The report gives the general income of the worldwide sepsis and shock treatment market for the period 2021-2028, thinking about 2020 as the base year and 2028 as the gauge year. The report additionally gives the build yearly development rate (CAGR) for the worldwide sepsis and shock treatment market for the gauge time frame. The report has been arranged after broad exploration. The essential examination included a greater part of exploration endeavors, wherein investigators did interviews with industry pioneers and assessment producers. The auxiliary examination included alluding to vital participants’ item writing, yearly reports, public statements, and important archives to comprehend the worldwide sepsis and shock treatment market. Receive the Sample Report of Sepsis And Septic Shock Treatment Market Insights 2022 to 2028 @ https://www.infinitybusinessinsights.com/request_sample.php?id=658521 The report involves an intricate chief rundown, alongside a preview of the development conduct of different sections and sub-fragments remembered for the extent of the review. Furthermore, the report reveals insight into the changing serious elements in the worldwide sepsis treatment market. These files act as important instruments for existing business sector players as well concerning elements keen on partaking in the worldwide sepsis and shock treatment market. The following segment of the worldwide sepsis and shock treatment market report features the USPs, which incorporate mechanical progressions, key industry occasions (consolidations, acquisitions, vital associations, and so on), the top three players working in the market space, and the COVID-19 pandemic effect on the worldwide sepsis and shock treatment market. Competitive Analysis Central membersVBI-S: Vivacelle BioNangibotide (LR12): InotremAllocetra: Enlivex TherapeuticsIdarucizumab: AdrenomedDetroja/Fetch Roja (Cefiderocol): ShionogiRecomodulin (ART-123): Asahi Kasei Pharma Corp.Recombinant human soluble phosphatase: AM-Pharma Division SegmentThe development among sections assists you with examining specialty pockets of development and systems to move toward the market and decide your center application regions and the distinction in your objective business sectors. Based on stages, the sepsis treatment market is fragmented into sepsis, serious sepsis, and septic shock. Based on microbe type, the sepsis treatment market is portioned into microorganisms, parasites, and infection. Based on the component of activity, the sepsis and shock treatment market is portioned into antimicrobials, corticosteroids, vasoactive specialists, analgesics and others. Coronavirus Impact AnalysisThe Global Sepsis and shock treatment have expressed that the novel Covid might prompt sepsis by influencing the body’s safe framework reaction toward the contamination, bringing about organ harm and even demise. Such advancements are setting out income open doors for partners in the sepsis treatment market. Coronavirus pneumonia is one of the main considerations to causes of sepsis in patients, attributable to serious lung aggravation that happens because of the original contamination. Bacterial, contagious, and viral diseases have the likelihood to cause Covid pneumonia, hence prompting sepsis. It has been tracked down that patients with extreme COVID-19 from Seattle revealed serious septic shock, which set off the interest for medications to help heart and blood courses. Download the Full Index of the Sepsis And Septic Shock Treatment Market Key Questions Answered in the ReportWhat are the deals/income created by sepsis makers across all locales during the gauge time frame?What are the critical patterns in the worldwide sepsis and shock treatment market?What are the significant drivers, restrictions, valuable open doors, and dangers on the lookout?What district is set to grow at the quickest CAGR during the figure time frame?Which portion will have the most noteworthy income around the world in 2028 and which fragment will extend at the most elevated CAGR during the conjecture time frame?What was the market positioning of various organizations working in the worldwide market in 2020? Contact Us:Amit JainSales Co-OrdinatorInternational: +1 518 300 3575Email: inquiry@infinitybusinessinsights.comWebsite: https://www.infinitybusinessinsights.com

  • Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021

    Vivacelle Bio named included in 101 top Illinois Biotechnology Companies and Startups - 2021 https://beststartup.us/101-top-illinois-biotechnology-companies-and-startups-of-2021/

bottom of page